Ritter appoints Michael Step as chief executive
Privately-held gastrointestinal company Ritter Pharmaceuticals has appointed Michael Step as chief executive.
He was appointed to the board of directors in 2011 and will continue to serve as a director, while Andrew Ritter, who founded the company and previously held the position of president and chief executive, will now be president and a director.
Mr Step brings more than 20 years’ experience in the pharma industry, and for the past nine years he served as senior vice president of corporate development and a member of the executive committee of Santarus until its sale to Salix (Nasdaq: SLXP) this year. Prior to this, he was vice president of corporate development and as executive director of commercial operations for Amlyn Pharmaceuticals, where he led the licensing agreement with Eli Lilly (NYSE: LLY) for Byetta (exenatide).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze